Brazil to produce measles and rubella vaccine for poor countries

RIO DE JANEIRO Mon Oct 28, 2013 5:51pm IST

Brazil's Minister of Health Alexandre Padilha reacts after a conference for foreign doctors at the University of Brasilia August 26, 2013. REUTERS/Ueslei Marcelino

Brazil's Minister of Health Alexandre Padilha reacts after a conference for foreign doctors at the University of Brasilia August 26, 2013.

Credit: Reuters/Ueslei Marcelino

Related Topics

Stocks

   

RIO DE JANEIRO (Reuters) - Brazil´s top biomedical research and development center announced plans on Monday to produce a combined measles and rubella vaccine for developing countries, mainly in Africa.

The first Brazilian vaccine developed specifically for export will be made by Bio-Manguinhos, a unit of the Oswaldo Cruz Foundation (Fiocruz), in partnership with the Bill & Melinda Gates Foundation.

Brazilian health minister Alexandre Padilha announced the vaccine plan at a medical science conference that the Gates Foundation organized in Rio de Janeiro.

Brazil is following other leading emerging nations such as China and India in investing in biomedical technology to supply vaccines and medicines to developing countries at lower costs than those produced by pharmaceutical industries in developed nations.

Measles kills 158,000 people a year in the world, mostly children under the age of five. Rubella, a contagious viral disease with symptoms like mild measles, can cause serious consequences to pregnant women and their babies.

Bio-Manguinhos, which has a track record of making combined measles, mumps and rubella vaccines, will produce 30 million doses per year of the new measles/rubella vaccine to supply developing countries in Africa, Asia and Latin America.

This will increase the availability of a vaccine that today is produced by only one manufacturer, the Serum Institute of India Ltd.

The Gates Foundation said it would grant $1.1 million to support clinical trials and might contribute additional funds in subsequent phases of the project.

Bio-Manguinhos has been producing the combined measles, mumps and rubella vaccine since 2003 under a technology transfer agreement with GlaxoSmithKline Plc. This triple vaccine is used in Brazil´s immunization program, but was not adopted in many developing countries due to its cost and the limited epidemiological presence of mumps in a number of them.

The new measles/rubella vaccine is aimed at that group of nations and is expected to reach the market by 2017.

(Reporting by Anthony Boadle; Editing by Lisa Von Ahn)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Bullying Impact

Reuters Showcase

A Little Help

A Little Help

Researchers "buzz" the brain to speed up learning.  Video 

Disease Outbreak

Disease Outbreak

WHO says West African Ebola outbreak to last 2-4 months.  Full Article 

Healthy Food

Healthy Food

For teen girls, fruits and veggies linked to lower risk of breast condition.  Full Article 

Milk Effect

Milk Effect

Drinking milk may slow women's knee arthritis.  Full Article 

Rising Obesity

Rising Obesity

U.S. childhood obesity rates have increased since 1999: study.  Full Article 

Quality Check

Quality Check

Just because it's sweet and sticky doesn't mean it's 'honey': FDA.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.   Full Coverage